Han Kyu Na

Han Kyu Na

Auto-generated profile, based on publicly available information

Han Kyu Na

Department of Neurology Yonsei University College of Medicine Seoul South Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SKSungwoo Kang
Sungwoo Kang
SYSo Hoon Yoon
So Hoon Yoon
HNHan Kyu Na
Han Kyu Na
YLYoung-gun Lee
Young-gun Lee
SJSeun Jeon
Seun Jeon
BYByoung Seok Ye
Byoung Seok Ye
Kang S, et al. J Clin Neurol. 2023 Apr;19:e33. https://doi.org/10.3988/jcn.2022.0358

27 January 2023 in Annals of Neurology
Verified
Journal Article
Closed access
HNHan Kyu Na
Han Kyu Na
HKHan‐Kyeol Kim
Han‐Kyeol Kim
HLHye Sun Lee
Hye Sun Lee
MPMina Park
Mina Park
JLJae-Hoon Lee
Jae-Hoon Lee
CLChul Hyoung Lyoo
Chul Hyoung Lyoo

24 December 2024 in Neurology
Verified
Journal Article
Closed access
HYHan Soo Yoo
Han Soo Yoo
HKHan-Kyeol Kim
Han-Kyeol Kim
HNHan Kyu Na
Han Kyu Na
SKSungwoo Kang
Sungwoo Kang
MPMina Park
Mina Park
CLChul Hyoung Lyoo
Chul Hyoung Lyoo
Parkinson disease (PD) shows degeneration of dopaminergic neurons in the substantia nigra and characteristic changes in brain metabolism. However, how they correlated and affect motor and cognitive dysfunction in PD has not yet been well elucidated. In this single-site cross-sectional study, we enrolled patients with PD who underwent N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (18F-FP-CIT) PET, 18F-fluorodeoxyglucose (18F-FDG) PET, the Movement Disorder Society-sponsored Unified PD Rating Scale examination, and detailed neuropsychological testing. General linear models and mediation analyses were implemented to investigate the association between striatal dopamine transporter availability, brain metabolism, and parkinsonian motor subscores or domain-specific cognitive scores. Healthy controls (HCs) who underwent 18F-FP-CIT and 18F-FDG PET were also enrolled. Compared with HCs (n = 38, mean age 67.3 ± 5.9 years; 19 women), patients with PD (n = 143, mean age 69.0 ± 9.0 years; 69 women) characteristically showed relative brain hypermetabolism and hypometabolism that correlated with striatal dopamine transporter availability. As the loss of putaminal dopamine transporter availability increased, brain metabolism relatively increased from the paracentral lobule, pons, and limbic system to the cerebellum and anterior cingulate cortex, whereas brain metabolism relatively decreased from the lateral temporal and frontal cortices to the occipital and inferior parietal cortices. Reduced putaminal dopamine was associated with a higher rigidity subscore by the mediation of relative hypermetabolism in the paracentral lobule (standardized indirect effect, β = -0.070, p = 0.025) and directly associated with a higher bradykinesia subscore (β = -0.274, p = 0.011). Reduced caudate dopamine was associated with a higher axial subscore (β = -0.125, p = 0.004) and lower executive (β = 0.229, p = 0.004), visuospatial (β = 0.139, p = 0.006), and memory (β = 0.140, p = 0.004) domain scores by the mediation of relative brain hypometabolism. The tremor subscore and language and attention scores were not associated with striatal dopamine availability or brain metabolism. Our findings suggest that in PD, striatal dopamine depletion and altered brain metabolism are closely linked, that changes in brain metabolism occur in specific spatial patterns depending on the degree of dopamine depletion, and that both differentially affect motor and cognitive dysfunction depending on each symptom.

22 February 2025 in Epilepsia
Verified
Journal Article
Open access
SCSoomi Cho
Soomi Cho
SSSeungwon Song
Seungwon Song
JYJungyon Yum
Jungyon Yum
EKEun Hwa Kim
Eun Hwa Kim
YRYun Ho Roh
Yun Ho Roh
KKKyung Min Kim
Kyung Min Kim
Objective: This study was undertaken to investigate the regional burden of enlarged perivascular spaces (EPVSs) in patients with temporal lobe epilepsy with hippocampal sclerosis (TLE‐HS) and explore its prognostic relevance. Methods: In this retrospective observational study, EPVSs in the temporal lobe (T‐EPVS), centrum semiovale (CS‐EPVS), basal ganglia (BG‐EPVS), midbrain, and hippocampus were visually rated in 68 treatment‐naïve patients with TLE‐HS. Regional EPVS burden was dichotomized into high and low degrees (cutoff: >10 for BG‐EPVS/T‐EPVS; >20 for CS‐EPVS). Cox proportional hazards models were used to determine the potential predictors of seizure freedom (SF; no seizure for >1 year) and delayed SF (SF achieved >6 months after initiating antiseizure medication [ASM]). Multivariate logistic regression using stepwise variable selection based on the Akaike information criterion was performed to investigate whether EPVS burden was associated with medical refractoriness (never achieving SF). Results: Of the 68 patients, 20 were classified into the refractory group (29.4%). The high T‐EPVS group had an older epilepsy onset (37.3 ± 12.3 vs. 26.5 ± 13.0 years, p = .005), higher pretreatment seizure density (median = 12.0, interquartile range [IQR] = 5.0–20.0 vs. 4.0, IQR = 2.0–10.5, p = .008), and lower focal to bilateral tonic–clonic seizure prevalence (13.3% vs. 73.6%, p < .001) than the low T‐EPVS group. High T‐EPVS burden (odds ratio [OR] = 10.908, 95% confidence interval [CI] = 1.895–62.789) was an independent predictor of medial refractoriness, along with female sex (OR = 12.906, 95% CI = 2.214–75.220) and ASM treatment duration (OR = .985, 95% CI = .971–.999). The low T‐EPVS group had higher probability of achieving delayed SF than the high T‐EPVS group ( p Log‐rank = .030, p Cox regression = .038), whereas the probability of achieving SF was comparable between the two groups ( p Log‐rank = .053, p Cox regression = .146). Significance: Increased T‐EPVS burden may serve as an imaging marker of unfavorable prognosis in patients with TLE‐HS, underscoring the potential role of perivascular dysfunction in diminished ASM response.

17 December 2022 in Movement Disorders
Verified
Journal Article
Closed access
KBKyoungwon Baik
Kyoungwon Baik
HKHye Ryun Kim
Hye Ryun Kim
MPMincheol Park
Mincheol Park
YLYoung-gun Lee
Young-gun Lee
HNHan Kyu Na
Han Kyu Na
PLPhil Hyu Lee
Phil Hyu Lee

4 November 2025 in European Journal of Neurology
Verified
Journal Article
Open access
YSYeeun Sun
Yeeun Sun
HNHan Kyu Na
Han Kyu Na
SYSo Hoon Yoon
So Hoon Yoon
QVQuynh Phuong Vo
Quynh Phuong Vo
CPChan Wook Park
Chan Wook Park
PLPhil Hyu Lee
Phil Hyu Lee
Background: While olfactory dysfunction is common in Parkinson disease (PD), its neural basis and clinical implications remain to be clarified. We investigated the neural substrates and clinical profiles, particularly non‐motor symptoms (NMSs), associated with olfactory function. Methods: This retrospective study included 259 drug‐naïve patients with PD who underwent the Cross‐Cultural Smell Identification Test (CC‐SIT), comprehensive autonomic function test, neuropsychological assessments, and the Neuropsychiatric Inventory Questionnaire (NPI‐Q) at diagnosis. NMS profiles were compared across olfactory groups defined by CC‐SIT scores (normosmia [ n = 45], hyposmia [ n = 143], anosmia [ n = 74]). Associations between olfaction and clinical/imaging variables were assessed using correlation and path analyses. Cox proportional hazards models were employed to evaluate the risk of developing motor complications or PD dementia according to olfactory status. Results: CC‐SIT scores correlated with Composite Autonomic Severity Scale scores (rho = −0.219, p = 0.001), NPI‐Q scores (rho = −0.269, p < 0.001), and cognitive performance in memory (rho = 0.288, p < 0.001) and frontal/executive domains (rho = 0.205, p = 0.001). Dopaminergic depletion in the caudate nucleus and limbic atrophy emerged as neural substrates underlying olfactory dysfunction, mediating the association between olfaction and cognitive/neuropsychiatric symptoms. Anosmia was associated with increased risk of developing PD dementia compared to normosmia (hazard ratio [HR]: 2.579; 95% confidence intervals [CI]: 1.137–5.851) and hyposmia (HR: 2.783; 95% CI: 1.437–5.390). Anosmia was associated with higher risk of developing freezing of gait (HR: 2.571; 95% CI: 1.077–6.134) compared to normosmia. Conclusions: Olfactory dysfunction serves as a multifaceted clinical marker associated with convergent degeneration of nigrostriatal and limbic pathways, offering insights into PD phenotypic variance and its prognostic implications.